[
  {
    "ts": null,
    "headline": "Will The Decline in Legacy Drugs Pull Down BMY's Top Line?",
    "summary": "Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.",
    "url": "https://finnhub.io/api/news?id=a4e387343a3a6918ad3fbf09e0437150305b11952c4db58010ec5bc441a4ebe3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751549160,
      "headline": "Will The Decline in Legacy Drugs Pull Down BMY's Top Line?",
      "id": 135735715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.",
      "url": "https://finnhub.io/api/news?id=a4e387343a3a6918ad3fbf09e0437150305b11952c4db58010ec5bc441a4ebe3"
    }
  },
  {
    "ts": null,
    "headline": "MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations",
    "summary": "Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.",
    "url": "https://finnhub.io/api/news?id=85a15a94cd5505582e052c2f873a8cad102025935f28ea3ea5272d0d2b744ca6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751547960,
      "headline": "MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations",
      "id": 135735857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.",
      "url": "https://finnhub.io/api/news?id=85a15a94cd5505582e052c2f873a8cad102025935f28ea3ea5272d0d2b744ca6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Trades Above 50-Day Average for a Month: Time to Buy?",
    "summary": "PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.",
    "url": "https://finnhub.io/api/news?id=a20a7d6e358ca1e63f0b7870ff6a32bb9b0c5b0baf6b2371d041d1915b3e3d71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751546880,
      "headline": "Pfizer Trades Above 50-Day Average for a Month: Time to Buy?",
      "id": 135735489,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.",
      "url": "https://finnhub.io/api/news?id=a20a7d6e358ca1e63f0b7870ff6a32bb9b0c5b0baf6b2371d041d1915b3e3d71"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma",
    "summary": "Lynozyfic can be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.",
    "url": "https://finnhub.io/api/news?id=7094989b37f7b267947e1092daa23c9e4b17471a9fea1376c7e624f1441b13b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751543043,
      "headline": "Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma",
      "id": 135735538,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Lynozyfic can be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.",
      "url": "https://finnhub.io/api/news?id=7094989b37f7b267947e1092daa23c9e4b17471a9fea1376c7e624f1441b13b0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Options Activity Speaks Bullish",
    "summary": "Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my updated look at PFE stock prospects.",
    "url": "https://finnhub.io/api/news?id=33579ee6517cde0c15f1f8de49560b97626d3bdb92edde78695e4e6e158bbb39",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751536408,
      "headline": "Pfizer: Options Activity Speaks Bullish",
      "id": 135732928,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my updated look at PFE stock prospects.",
      "url": "https://finnhub.io/api/news?id=33579ee6517cde0c15f1f8de49560b97626d3bdb92edde78695e4e6e158bbb39"
    }
  },
  {
    "ts": null,
    "headline": "Robert F. Kennedy Jr. Just Did The Unexpected. He Helped Moderna.",
    "summary": "Robert F. Kennedy Jr. Just Did The Unexpected. He Helped Moderna.",
    "url": "https://finnhub.io/api/news?id=86030c3f5e1e111f262b4bcdff993d884547e27ed40a73f1d0cf7baf1fa927e9",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751535362,
      "headline": "Robert F. Kennedy Jr. Just Did The Unexpected. He Helped Moderna.",
      "id": 135814063,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "Robert F. Kennedy Jr. Just Did The Unexpected. He Helped Moderna.",
      "url": "https://finnhub.io/api/news?id=86030c3f5e1e111f262b4bcdff993d884547e27ed40a73f1d0cf7baf1fa927e9"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Stock a Yield Trap?",
    "summary": "Shares of Pfizer offer a yield above 7% at recent prices.  Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009.  Loss of patent-protected exclusivity for several blockbuster drugs is expected to reduce Pfizer's sales a great deal over the next few years.",
    "url": "https://finnhub.io/api/news?id=a25c1fe253279e3aa9010580ee15cd11ab6b05d8b782d0b8187aac08f527acc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751530860,
      "headline": "Is Pfizer Stock a Yield Trap?",
      "id": 135735860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares of Pfizer offer a yield above 7% at recent prices.  Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009.  Loss of patent-protected exclusivity for several blockbuster drugs is expected to reduce Pfizer's sales a great deal over the next few years.",
      "url": "https://finnhub.io/api/news?id=a25c1fe253279e3aa9010580ee15cd11ab6b05d8b782d0b8187aac08f527acc0"
    }
  },
  {
    "ts": null,
    "headline": "Actinium Highlights ATNM 400 Progress at SNMMI Conference",
    "summary": "Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans, Actinium Pharmaceuticals, Inc. (NYSE:ATNM) showcased promising preclinical results for its prostate cancer candidate, ATNM-400. The data indicated that the leading drug demonstrated superior […]",
    "url": "https://finnhub.io/api/news?id=a2f4860e6a4e99e15543629578758325b1644a2bbbc81b54ec60e5c019eb89a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751508351,
      "headline": "Actinium Highlights ATNM 400 Progress at SNMMI Conference",
      "id": 135719779,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans, Actinium Pharmaceuticals, Inc. (NYSE:ATNM) showcased promising preclinical results for its prostate cancer candidate, ATNM-400. The data indicated that the leading drug demonstrated superior […]",
      "url": "https://finnhub.io/api/news?id=a2f4860e6a4e99e15543629578758325b1644a2bbbc81b54ec60e5c019eb89a7"
    }
  }
]